But who doesn’t need a little constructive criticism? From the same Dutch company that gave us the Access to Medicine Index, comes a new benchmarking report for the vaccine manufacturers out there. The comprehensive analysis rates manufacturer performance on 3 criteria including Pricing, R&D, and Manufacturing/Supply. Wondering how you rank in the report? Sneak peek: GSK is killing it, Pfizer…not so much. Also included in the analysis is market outlook, priority diseases, and a look at access in underdeveloped global regions. A pretty informative read, not to mention free! (Not a product endorsement, we promise).
In creating its 2017 formulary, the pharmacy benefits manager CVS Health, said “Hit the road, Jack,” to a number of drugs. Some products like Sanofi’s insulin blockbuster Lantus and Amgen’s Neupogen were given the boot in favor of biosimilar counterparts. Ten other drugs were left high and dry for being “hyperinflationary,” including several drugs made by Valeant, Concordia, and Novum Pharma. Some rare disease and cancer drugs were also nixed. These formulary cuts should translate to cost savings for CVS Health but are worrisome for patients who may no longer have access to needed products. This is also concerning for drug makers, particularly if other PBMs follow suit.